Results 201 to 210 of about 3,365,654 (307)
Lifestyle Management in Menopause: A Systematic Review of Women With Premature Ovarian Insufficiency
ABSTRACT Objective Premature ovarian insufficiency (POI), the loss of ovarian function before age 40, increases the risk of cardiovascular disease, low bone mineral density, dementia and psychological distress. Lifestyle interventions reduce chronic disease risk in other populations and, with hormone therapy, may improve health outcomes in POI.
Ladan Yeganeh +4 more
wiley +1 more source
Effects of ABCG2 dysfunction on hyperuricemia progression in premenopausal and postmenopausal women. [PDF]
Miyoshi Y +22 more
europepmc +1 more source
ABSTRACT Background Postmenopausal osteoporosis associated with cafeteria diet and bisphosphonate therapy may impair peri‐implant bone repair. Therefore, strategies to enhance osseointegration are needed. Aim This study investigated whether teriparatide‐coated implant surfaces enhance osseointegration in a rodent model of estrogen deficiency (OVX) and ...
Ana Cláudia Ervolino da Silva +9 more
wiley +1 more source
Multidimensional sleep behaviours and incident obesity in postmenopausal women: a prospective cohort study. [PDF]
Zhu M, Liu S, Gang X, Wang Y.
europepmc +1 more source
Comparative Effectiveness of Empiric Antibiotics for Uncomplicated Urinary Tract Infection in Postmenopausal Women. [PDF]
Lacsamana JM +5 more
europepmc +1 more source
ABSTRACT Aim Oxytocin has been proposed to exert glucose‐stabilising effects via modulation of pancreatic hormone secretion and to play a role in bone homeostasis. However, human data under controlled conditions are limited. We investigated the effects of intravenously infused oxytocin during a graded glucose infusion on glucose‐regulating hormones and
Vivian Kliim‐Hansen +9 more
wiley +1 more source
The impact of calcium supplementation on hypertension management in postmenopausal women with hypocalcemia. [PDF]
Alaarag AF +6 more
europepmc +1 more source
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1RA and triple (GIP)/GLP‐1RA/glucagon agonists achieve placebo‐subtracted weight loss of 15% to 22%. Their long‐term value depends on how well the weight loss is maintained and on the composition of weight loss, not only
Michael Zitzmann +3 more
wiley +1 more source

